Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma
Open Access
- 24 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 17 (8), 941-943
- https://doi.org/10.1038/nm.2407
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell LymphomaCancer Cell, 2010
- BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-like Diffuse Large B Cell LymphomaCancer Cell, 2010
- A map of human genome variation from population-scale sequencingNature, 2010
- Subsequent Neoplasms in 5-Year Survivors of Childhood Cancer: The Childhood Cancer Survivor StudyJNCI Journal of the National Cancer Institute, 2010
- Gene–environment-wide association studies: emerging approachesNature Reviews Genetics, 2010
- Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin DiseaseJama-Journal Of The American Medical Association, 2003
- Second Malignant Neoplasms in Five-Year Survivors of Childhood Cancer: Childhood Cancer Survivor StudyJNCI Journal of the National Cancer Institute, 2001
- Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease.2000
- Genomic Control for Association StudiesBiometrics, 1999
- Repression of c- myc Transcription by Blimp-1, an Inducer of Terminal B Cell DifferentiationScience, 1997